Pembrolizumab plus axitinib combination promising as a first-line treatment for advanced RCC
Results from the KEYNOTE-426 phase 3 study show that the [...]
ESMO 2018: Avelumab plus axitinib combination shows great promise as first-line treatment for advanced RCC
Results from the JAVELIN Renal 101 phase 3 study to [...]
ESMO 2018: Adjuvant axitinib versus placebo in patients at high risk of RCC recurrance
Results from the latest adjuvant study with a vascular endothelial [...]
Neoadjuvant axitinib shrinks kidney tumours to allow for partial nephrectomy
A recent phase II study of 18 patients with clear-cell renal [...]
Vegan diet and cancer
The following review article from Cancer Therapy Advisor summarises three [...]
UK doctors allowed to prescribe medical cannabis
A change in the law will allow specialist clinicians to [...]
Cabozantinib declined for use within NHS Scotland for first-line treatment of advanced kidney cancer
We are very disappointed by the Scottish Medicines Consortium's (SMC) [...]
Epacadostat plus pembrolizumab combination shows promise in advanced solid tumours
Headline results from the open-label phase I/II ECHO-202/KEYNOTE-037 trial assessing [...]
Synthetic or plant-based cannabis for symptom relief in patients with cancer
This article discusses the evidence available for synthetic and plant-based [...]
Potential biomarker for kidney cancer survival identified
A recent paper from researchers in China and published in [...]
